Effect of Combining Impact-Aerobic and Strength Exercise, and Dietary Habits on Body Composition in Breast Cancer Survivors Treated with Aromatase Inhibitors

Int J Environ Res Public Health. 2023 Mar 10;20(6):4872. doi: 10.3390/ijerph20064872.

Abstract

This study examines both the effect of a twice-weekly combined exercise-1 h session of strength and 1 h session of impact-aerobic-on body composition and dietary habits after one year of treatment with aromatase inhibitors (AI) in breast cancer survivors. Overall, forty-three postmenopausal women with a BMI ≤ 35 kg/m2, breast cancer survivors treated with AI, were randomized into two groups: a control group (CG) (n = 22) and a training group (IG) (n = 21). Body composition, i.e., abdominal, visceral, and subcutaneous adipose tissue) was measured by magnetic resonance. In addition, some questionnaires were used to gather dietary data and to measure adherence to the Mediterranean diet. After one year, women in the IG showed a significant improvement in body composition, indicated by decreases in subcutaneous and visceral adipose tissue, and total fat tissue. Furthermore, the dietary habits were compatible with moderate adherence to the Mediterranean diet pattern and a low dietary intake of Ca, Zn, Folic Ac, and vitamins D, A, and E. A twice-weekly training program combining impact aerobic exercise and resistance exercise may be effective in improving the body composition for postmenopausal women who have breast cancer treated with AI, and the results suggest the need for nutritional counselling for this population.

Keywords: aromatase inhibitors; body composition; breast cancer survivors; combined exercise; dietary habits; impact-aerobic exercise; strength exercise.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aromatase Inhibitors / therapeutic use
  • Body Composition
  • Breast Neoplasms* / therapy
  • Cancer Survivors*
  • Exercise
  • Feeding Behavior
  • Female
  • Humans

Substances

  • Aromatase Inhibitors

Grants and funding

This research was funded by the Fundación Bancaria Caja Navarra, Grant No. 70673. Fundación Bancaria Caja Navarra had no role in the design, analysis, or writing of this article.